Pregabalin Capsule
Product Images NDC 60760-205

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 60760-205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregaba (Pregabalin 60760 205 60)

Label for Pregabalin Capsules 50 mg in a 60-count package, labeled by St. Mary's Medical Park Pharmacy. The label includes the product name, strength, quantity, NDC 60760-205-60, barcode, and storage instructions for controlled room temperature (15°-30°C). Manufacturer noted as ScieGen Pharmaceuticals, Inc.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph illustrates varying effectiveness of different Pregabalin dosages on pain improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day with placebo, with the Pregabalin group showing higher patient improvement across various pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph displaying the percent of patients improved by percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice a day, compared to a placebo. The x-axis represents percent improvement in pain from baseline, while the y-axis shows the percent of patients improved.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups, with the highest improvement seen in the 200 mg group, intermediate in the 100 mg group, and lowest in the placebo group.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating the percentage distribution of pain improvement across these treatments.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart showing responder rates (%) in two clinical studies (E1 and E3) for Pregabalin at various dosages compared to placebo. The x-axis lists treatment groups by dosage and frequency, while the y-axis indicates responder rate percentages. Statistically significant differences versus placebo are noted.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percentage change from baseline across different doses (mg/day) of a drug. The graph compares four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, using distinct markers. Significant p-values are indicated at various dose points. The x-axis represents dose in mg/day, and the y-axis shows seizure reduction percent. Placebo dose is noted as 0 mg/day.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Four lines represent different treatment groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo. The y-axis shows percent of patients improved (0 to 100%), and the x-axis shows percent improvement in pain from baseline (0 to 100%). Two vertical lines mark percent improvement thresholds at 30% and 50%.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve chart comparing Pregabalin and Placebo groups. The x-axis represents Days from 0 to 180, and the y-axis shows the Estimated Percentage of Subjects Without LTR from 0% to 100%. Two lines indicate higher survival without LTR for Pregabalin than Placebo over time.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line chart comparing the percent of subjects improved on Pregabalin versus placebo. The x-axis represents percent improvement from baseline to Week 12 BOCF, from 0 to 100 percent. The y-axis shows percent of subjects improved, also from 0 to 100 percent. The solid line for Pregabalin shows a higher percentage of subjects improved compared to the dashed line for placebo across improvement levels.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved from baseline to Week 16 between Pregabalin and placebo groups. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved. The graph depicts two lines: a solid line for Pregabalin and a dashed line for placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A mathematical formula for calculating creatinine clearance (CLcr) based on age, weight, serum creatinine, and a gender adjustment factor for females. The formula is presented in a clear typed format.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure diagram of Pregabalin, showing its molecular configuration with labeled functional groups including an amino group and a carboxyl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.